Vanda Pharmaceuticals, Inc. (VNDA) Posts Wider than Expected Q3 Loss
Tweet
Share
E-mailGet Alerts VNDA Hot Sheet
Price: $5.92 -0.5%
Revenue Growth %: +17.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Revenue Growth %: +17.5%
Financial Fact:
Net income (loss): -430K
Today's EPS Names:
DTGI, CRMT, MAYS, More
Join SI Premium – FREE
Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA) reported Q3 EPS of ($0.11), $0.03 worse than the analyst estimate of ($0.08). Revenue for the quarter came in at $8 million versus the consensus estimate of $8.26 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat
- KB Home (KBH) Misses Q2 EPS by 2c; Offers Outlook
- Cerebras Q1 EPS miss sends shares down 9% after-hours
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
